Drug
Levosimendan Infusion
Levosimendan Infusion: highest development phase Post-Market, developed by Orion Corporation. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Orion Corporation
Trials
| Drug | Phase | Indication |
|---|---|---|
| Levosimendan infusion NCT01318460 | Post-Market | Coronary Artery Disease |
Latest
No recent events.
Follow Levosimendan Infusion on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.